DOCSLIB.ORG

ATS 2019 Poster-Measuring the Early Impact on Transmission

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Measuring the Early Impact on Transmission of New Treatment Regimens for Drug Resistant Tuberculosis Edward A. Nardell 1, Elsabé J.E de Kock2, Ruvandhi R. Nathavitharana3, Paul A. Jensen4, Carl Mendell5, Mel Spigelman5, and Anton C. Stoltz6 (1) Division of Global Health Equity, Brigham & Women’s Hospital, Harvard Medical School,Boston, USA; (2) Retrasol, Pretoria, South Africa; (3) Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston USA; (4) Centers for -1 Disease Control, Atlanta, USA; Global Alliance for Drug Development; (5) TB Alliance, New York, USA; and (6) Division Infectious Diseases, University of Pretoria, Pretoria, South Africa Study funded by NIAID: RO1AI099603, PI Anton Stoltz, MD, PhD BACKGROUND EXPERIMENTAL DESIGN SUBJECTS Experiment 1 Experiment 2 Since the classic human-to-guinea (H-GP) pig transmission Airborne Infections Research (AIR) Facility, Mpumalanga, South Africa PT # Line Probe TB treatment PT # Line Probe / TB treatment ABSTRACT experiments of Riley and colleagues in Baltimore 60 years Experimental Design: Testing the impact of treatment on algorithm Bedaquiline 400mg bd for 2 Reason for starting ago, effective treatment has been known to stop M. weeks then 400 q.d. NIX Human to Guinea Pig MDR/XDR-Mtb Transmission • PZA 1,5g, • Pretomanid 200mg tuberculosis (Mtb) transmission almost immediately – well • Levofloxacin 1g, Newly diagnosed q.d. • Teridizone 500mg, Rif Resistant • Linezolid 1200mg 1/01 katGmut1; inhA 2/01 before 2-weeks of treatment, or sputum smear and culture 5 hospitalized smear and culture positive MDR treatment • Linezolid 600mg, GeneXpert q.d. 1 failure patients being evaluated for XDR treatment • Clofazamine 100mg Not yet on treatment • Bedaquiline 400mg Rationale: Most multidrug and extensively-drug resistant conversion at about 2-months. Epidemiological observations • Bedaquiline 400mg q.d. tuberculosis (MDR- and XDR-TB) occurs due to confirmed the rapid impact of effective treatment Mtb on • PZA 1,5g, 8 days exposure of • Levofloxacin 1g, • Pretomanid 200mg transmission of unsuspected or ineffectively treated DR- 2 Result: • Terivalidin 500mg, KatG 2016; treated q.d. spread. Retrospective observations at the South African 90 naïve guinea pigs katGmut1; 24 of 90 guinea pigs • Ethonamide 500mg, Oct-Dec 2016 • Linezolid 1200mg TB. Recently, results from the NiX-TB study in South 1/02 inhAmut1; 2/02 Airborne Infection Research (AIR) Facility indicate that infected • INH 900mg x3xw, 1+ pos q.d. Africa demonstrated durable cure at 6 months in 89% of pre- treatment pre-XDR treatment rpoBmut3 of patients • Capreomycin 500mg Not yet on treatment • Bedaquiline 400mg patients with multidrug-resistant tuberculosis (MDR-TB), like of patients • Linezolid 600mg, q.d. XDR-TB patients. The duration of treatment needed to Chamber A drug susceptible TB, become rapidly non-infectious soon • Bedaquiline 400mg stop person to person spread of DR-TB is not known, but • PZA 1,5g 72 hr treatment initiation • Pretomanid 200mg 3,4 • Levofloxacin 1g Newly diagnosed is critical to the potential for ambulatory management. (less than 72 hours) after starting effective anti-TB therapy. katGmut1; q.d. • Terivalidin 500mg Rif resistant 8 days exposure of inhA; inhAWT2; • Linezolid 1200mg Using the human-guinea pig (H-GP) transmission model, These data supported the ambulatory treatment of DS and Result: 1/03 • Linezolid 600mg 2/03 GeneXpert 90 naïve guinea pigs 25 of 90 guinea pigs rpoBmut1; q.d. • Ethambutol 800mg Hearing loss; Not yet Riley showed almost immediate transmission cessation of infected katGWT, katG • Bedaquiline 400mg DR TB. However, at ATS 2017, we presented H-GP evidence • Linezolid 600mg, on treatment patients on-XDR Interpretation: 13 days q.d. drug susceptible TB in response to effective treatment, • Bedaquiline 400mg that patients in South Africa with MDR-TB treatment failure treatment Bedaquilline/Linazolid • Pretomanid 200mg and we showed similar findings, retrospectively, for MDR- treatment had no • PZA 1,5g Chamber B Rif resistant q.d. (some with XDR-TB) continued to transmit after bedaquiline impact on transmission • Levofloxacin 1g TB. We sought to evaluate the impact of novel DR-TB katGmut1; GeneXpert • Linezolid 1200mg • Clofazamine 100mg (BDQ) and linezolid (LZD) were added for 11 days (data 1/04 inhA; inhAWT2; 2/04 Pre-XDR q.d. regimens including NiX-TB on transmission using the H- • Terivalidin 500mg rpoBmut1; katG AFB 3+" • Bedaquiline 400mg • Linezolid 600mg GP transmission model. shown here as Experiment 1). We sought to test the rapid Not yet on treatment q.d. effects on transmission of the “NIX-TB” regimen – an entirely • Bedaquiline 400mg • PZA 1,5g • Pretomanid 200mg Methods: We admitted smear positive DR-TB patients to • Terivalidin 500mg oral regimen shown in a recent treatment trial to result in q.d. • Levofloxacin 1g Rif resistant the H-GP facility and measured baseline infectivity by 3 • Linezolid 1200mg clinical cure in 6-mos, and rapid sputum smear and culture Fig 1 The same protocol was used for both experiments. Patients were Rifampicin • Clofazamine 100mg Pre-XDR 1/05 2/05 q.d. exhausting ward air to one of two GP exposure rooms resistant • Ethonamide 500mg AFB 3+ (2 May); AFB admitted to the AIR facility to establish baseline, pre-treatment infectiousness • Bedaquiline 400mg conversion. The results have important implications for the • Capreomycin 750mg 2+ (Control), each containing 90 GPs. In Experiment 1, q.d. safety of community-based treatment and the ability of for 90 guinea pigs in exposure chamber A (approximately 40 patient-days). • Linezolid 600mg (presented at ATS, 2017) patients were initiated on an • Bedaquiline 400mg optimized DR-TB regimen including bedaquiline (BDQ) certain drugs or regimens to interrupt the largely unknown Then, for 3 days GP exposure was stopped and all patients were started on • Pretomanid 200mg q.d. Rif resistant and linezolid (LZD) based on the South African national mechanisms of transmission. treatment. Then, exposure of 90 GPs in chamber B started as treatment • Linezolid 1200mg 2/06 GeneXpert q.d. guidelines at that time. In Experiment 2, patients were continued for another 40 patient-days. Outcomes: GP TST reactions of 6 mm XDR-TB • Bedaquiline 400mg initiated on the NiX-TB regimen, consisting of BDQ, high or more were considered positive indicating infection (transmission). q.d. dose LZD and pretomanid. During the initial 72 hours of METHODS • Pretomanid 200mg q.d. Hearing loss treatment, no ward air was exhausted to either animal • Linezolid 1200mg 2/07 MDR, Rif resist Exp. 1. Add BDQ/LZN to a failed MDR-TB regimen q.d. room. After 72 hours, ward air was exhausted to the RESULTS GeneXpert We selectively admitted 5 Mtb, mostly smear positive • Bedaquiline 400mg second GP exposure room (Intervention). Infectiousness, q.d. over an average of 8 patient-days per participant patients, potentially bedaquiline suitable, to the AIR facility Rif resistant • Pretomanid 200mg GeneXpert q.d. (observation window) before and after starting DR-TB and measured baseline infectivity for an average of 8 days, Failing MDR • Linezolid 1200mg 2/08 treatment in the same patients, was compared by treatment q.d. by exhausting ward air to one of two guinea pig exposure AFB+ • Bedaquiline 400mg performing tuberculin skin tests (TST) in GPs at baseline chambers (Control), each containing 90 Hartley guinea pigs. q.d. and 6 weeks following the end of the exposure. • Pretomanid 200mg q.d. Once bedaquiline suitability was confirmed, and pre- Rif resistant • Linezolid 1200mg 2/09 GeneXpert treatment clinical evaluation completed, patients were q.d. Results: In Experiment 1 (see Figure), pre-treatment, five AFB+++ • Bedaquiline 400mg DR-TB patients infected 24 of 90 (26.7%) GPs (Control). initiated on standard South African treatment, including q.d. Post-treatment (72 hours after drug initiation), the same bedaquiline and linezolid, amongst others. patients (minus one who was withdrawn) infected 25 of 90 Table 1 lists the indications for re-treatment in Experiments 1 and 2, (27.8%) GPs (Intervention) (p = 1.00). In Experiment 2 During the initial 72 hours of treatment, no ward air was and the details of TB treatment. In experiment 1, retreatment was the (see Figure), pre-treatment, nine DR-TB patients infected exhausted to either animal room. After 72 hours, ward air 40 of 90 (44.4%) GPs (Control). Post-treatment (72 hours addition of BDQ/LZD to whatever other drugs were believed to be still after drug initiation), the same patients infected 0 of 90 was exhausted to the second guinea pig exposure chamber susceptible or had not been previously used, as per RSA MOH (0%) GPs (Intervention) (p < 0.0001). are pending. (Intervention) for an average of 8 days. Infectiousness during protocol. For experiment 2, patients were all started on the same exposure before and after starting MDR/XDR treatment in the NIX-TB oral regimen. Conclusions: South African DR-TB drug same patients, was compared by Guinea Pig tuberculin skin regimens that included BDQ and standard dose LZD did test (TST, 100 TU) induration, 6 weeks following the end of not decrease DR-TB transmission to GPs during the exposure. Note that one patient was withdrawn early, during observation window. In contrast, transmission was rapidly CONCLUSION & DISCUSSION and completely inhibited in patients treated with the NiX- the baseline infectivity period and subsequently passed, not contributing to guinea pig exposure during BDQ/LZD TB regimen. That is, patients did not transmit DR-TB to DISCUSSION/CONCLUSION South African DR-TB drug regimens that included BDQ and standard dose LZD did not decrease DR-TB transmission to GPs during the treatment. Note: indications for BDQ/LZD treatment includes GPs during the observation window, suggesting an early observation window. In contrast, transmission was rapidly and completely inhibited in patients treated with the “NiX-TB” regimen. That and profound impact on transmission. high level INH resistance. is, patients did not transmit DR-TB to GPs during the observation window, suggesting an early and profound impact on transmission.
Recommended publications

  • The T-SPOT.TB Test Frequently Asked Questions

    General tuberculosis information T-SPOT.TB Test description and Frequently asked performance questions T-SPOT.TB Test performance characteristics T-SPOT.TB advantages over tuberculin skin test T-SPOT.TB test results T-SPOT.TB methodology Screening control programs Contact investigations References References Table of contents General tuberculosis information Tuberculosis: Definition, infection and disease 1. What is the scale of the TB problem? 2. How is TB spread? 3. What is TB infection (Latent Tuberculosis Infection “LTBI” or “latent TB”)? 4. What is TB disease (“active TB”)? 5. Are certain groups of individuals at an increased risk of exposure to Mycobacterium tuberculosis? 6. Are certain individuals at an increased risk of progressing from latent TB infection to TB disease? 7. How important is treatment for TB disease? 8. Why is the treatment period for TB disease so long? 9. How important is treatment for TB infection (“LTBI” or “latent TB”)? TB detection 10. Is there a test for the detection of TB infection (“LTBI” or “latent TB”)? • Tuberculin Skin Test (TST) • Interferon-Gamma Release Assays (IGRA) 11. Is there a test for the detection of TB disease (“active TB”)? 12. What are the limitations of the TST? Bacille Calmette-Guérin (BCG) vaccination 13. What is the BCG vaccination? T-SPOT.TB test description and performance 14. What is the intended use of the T-SPOT.TB test? 15. Why does the T-SPOT.TB test measure interferon-gamma? 16. Does the T-SPOT.TB test differentiate between latent TB infection and TB disease? 17. What data is there to support the T-SPOT.TB test in clinical use? 18.
  • Faqs 1. What Is a 2-Step TB Skin Test (TST)? Tuberculin Skin Test (TST

    Faqs 1. What Is a 2-Step TB Skin Test (TST)? Tuberculin Skin Test (TST

    FAQs 1. What is a 2-step TB skin test (TST)? Tuberculin Skin Test (TST) is a screening method developed to evaluate an individual’s status for active Tuberculosis (TB) or Latent TB infection. A 2-Step TST is recommended for initial skin testing of adults who will be periodically retested, such as healthcare workers. A 2 step is defined as two TST’s done within 1month of each other. 2. What is the procedure for 2-step TB skin test? Both step 1 and step 2 of the 2 step TB skin test must be completed within 28 days. See the description below. STEP 1 Visit 1, Day 1 Administer first TST following proper protocol A dose of PPD antigen is applied under the skin Visit 2, Day 3 (or 48-72 hours after placement of PPD) The TST test is read o Negative - a second TST is needed. Retest in 1 to 3 weeks after first TST result is read. o Positive - consider TB infected, no second TST needed; the following is needed: - A chest X-ray and medical evaluation by a physician is necessary. If the individual is asymptomatic and the chest X-ray indicates no active disease, the individual will be referred to the health department. STEP 2 Visit 3, Day 7-21 (TST may be repeated 7-21 days after first TB skin test is re ad) A second TST is performed: another dose of PPD antigen is applied under the skin Visit 4, 48-72 hours after the second TST placement The second test is read.
  • Prior Tuberculin Skin Testing Does Not Boost Quantiferon-TB Results in Paediatric Contacts

    Prior Tuberculin Skin Testing Does Not Boost Quantiferon-TB Results in Paediatric Contacts

    REFERENCES 4 Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium 1 Suissa S, Ernst P, Vandemheen KL, Aaron SD. in combination with placebo, salmeterol, or fluticasone– Methodological issues in therapeutic trials of COPD. Eur salmeterol for treatment of chronic obstructive pulmonary Respir J 2008; 31: 927–933. disease: a randomized trial. Ann Intern Med 2007; 146: 2 Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids 545–555. 5 Wedzicha JA, Calverley PM, Seemungal TA, et al. The and mortality in chronic obstructive pulmonary disease. prevention of chronic obstructive pulmonary disease exacer- Thorax 2005; 60: 992–997. bations by salmeterol/fluticasone propionate or tiotropium 3 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and bromide. Am J Respir Crit Care Med 2008; 177: 19–26. fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789. DOI: 10.1183/09031936.00030508 Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts To the Editors: children were evaluated with TST and QFT-GIT. At the first visit, 63 (77.8%) contacts were QFT-GIT negative, eight (9.9%) We read with interest the paper by LEYTEN et al. [1], which were QFT-GIT positive and 10 (12.3%) had an undetermined appeared in the June 2007 issue of the European Respiratory QFT-GIT. Of those initially negative children, only one became Journal (ERJ). LEYTEN et al. [1] showed that prior tuberculin skin QFT-GIT positive after TST. The mean IFN-c antigen-specific 1 tests (TST) do not induce false-positive QuantiFERON -TB production did not change 11 weeks after skin testing (ESAT-6/ Gold in-tube (QFT-GIT) assay results when evaluated in the CFP-10/TB7.7 difference -0.030 IU?mL-1,p50.281).
  • Mdr Tb Exposure Screening and Treatment Recommendations

    Mdr Tb Exposure Screening and Treatment Recommendations

    Screening and Treatment Recommendations for People Exposed to Multidrug Resistant TB All people at increased risk of tuberculosis (TB) infection should be screened for TB infection per United States Preventive Services Task Force [1] and Centers for Disease Control and Prevention guidelines [2]. This document provides specific guidance for screening and post- screening management of all people who have been identified through public health investigations as having been exposed to multidrug resistant tuberculosis (MDR TB). Recommendations for symptomatic contacts, children less than 5 years of age and those who are highly immunocompromised (see step 1B) are different from other groups. Step 1: Initial Screening A. Assess contacts for symptoms of active TB disease ▪ Cough lasting 3 weeks or longer ▪ Contacts reporting cough of less than 3 weeks duration at the time of screening should have follow-up to determine if the cough has resolved. If they have a persistent cough for greater than or equal to 3 weeks, further evaluation is indicated. ▪ Hemoptysis (coughing up blood) ▪ Chest pain ▪ Night sweats ▪ Fevers or chills ▪ Unintentional weight loss ▪ Loss of appetite ▪ Fatigue B. Obtain a medical history including prior TB screening and TB treatment information ▪ Contacts with prior positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA) results (documentation of previous testing is recommended) do not need a new TST or IGRA performed; they should be considered to have a positive TB screening test. In the event a person with a past positive TST or IGRA has a new TST or IGRA performed and it is negative, the significance of the new screening test is uncertain.
  • Faqs for Health Professionals Quantiferon®-TB Gold Plus

    Faqs for Health Professionals Quantiferon®-TB Gold Plus

    FAQs for Health Professionals QuantiFERON®-TB Gold Plus Sample to Insight Contents Questions and answers 4 About TB 4 What is latent TB? And how is it different from active TB disease? 4 What is the meaning of ‘remote’ or ‘recent’ TB infection and can QFT distinguish between remote and recent infection? 5 Why is latent TB infection important? 5 How should screening for TB and LTBI be prioritized? 5 Is latent TB contagious? 7 Doesn’t everybody in high-incidence countries have latent TB? 7 About QFT-Plus 8 What is QFT-Plus? 8 What is the intended use of QFT-Plus? 8 How does QFT-Plus differ from QFT 9 What is the benefit of detecting immune responses from CD8 T cells 10 Why not have only CD8 T cell response in TB2 instead of CD4 and CD8? 10 Has TB7.7 been removed? Why? 10 Why the fourth tube? 10 In what clinical situations can QFT-Plus be used? 11 Can QFT-Plus distinguish between active TB and LTBI? 12 How does it work? 12 Why measure interferon-gamma? 12 How does QFT-Plus differ from the TST? 12 How long does it take to get QFT-Plus results? 13 Does a prior TST influence a QFT-Plus result? 14 What is the minimum time necessary to wait between exposure to M. tuberculosis and QFT-Plus testing? 14 Why do you include a positive control? How does this work? 14 What approvals does QFT-Plus have? 14 What is the evidence supporting QFT and QFT-Plus? 15 2 QuantiFERON-TB Gold Plus FAQ for Health Professionals 09/2017 Sensitivity and specificity of QFT-Plus 15 Why is it important to have a test with high specificity? 15 QFT-Plus procedure 17 What
  • Robert Koch from Obscurity to Glory to Fiasco

    Robert Koch from Obscurity to Glory to Fiasco

    Robert Koch From Obscurity to Glory to Fiasco Martin Dworkin Professor Emeritus, MicroBiology University of Minnesota Article Number: 1 Date of publication: October 5, 2011 Follow this and additional works at: http://purl.umn.edu/148010 Recommended Citation: Dworkin, Martin (2013). Robert Koch From Obscurity to Glory to Fiasco, Journal of Opinions, Ideas, and Essays. October 5.2011 Article #1. Available at http://purl.umn.edu/148010. Submissions will be accepted from any member of the University of Minnesota community. Access will be free and open to all. ROBERT KOCH: FROM OBSCURITY TO GLORY TO FIASCO Martin Dworkin Department of Microbiology University of Minnesota The Early Years Nunquam otiosus (21) Robert Koch was born in 1843 in Clausthal, Germany, a small mining city in Lower Saxony. His father was a mining engineer and Robert was one of eleven surviving children. During his early education he decided to become a teacher but always had an inclination toward natural science. Shortly after entering the University of Gottingen, one of Germany’s leading universities, his interactions with such great scientists as Henle, Wohler, and Meissner convinced him that natural science was to be his destiny. However, practical considerations led him to study medicine. While it became quickly clear that he had a talent for experimentation, Koch was a practical man and his impending marriage to Emmy Fraatz made it clear that a steady source of income was a reality. After completing his medical studies in 1866, Koch took and passed the state medical examination and became licensed to practice medicine. During the next six years he had five different positions as a practicing physician.
  • Tuberculin Skin Test and Quantiferon-Gold in Tube Assay

    Tuberculin Skin Test and Quantiferon-Gold in Tube Assay

    RESEARCH ARTICLE Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting Padmapriyadarsini Chandrasekaran1*, Vidya Mave2,3, Kannan Thiruvengadam1, Nikhil Gupte2,3, Shri Vijay Bala Yogendra Shivakumar4, Luke Elizabeth Hanna1, Vandana Kulkarni3, Dileep Kadam5, Kavitha Dhanasekaran1, Mandar Paradkar3, a1111111111 Beena Thomas1, Rewa Kohli3, Chandrakumar Dolla1, Renu Bharadwaj5, Gomathi a1111111111 Narayan Sivaramakrishnan1, Neeta Pradhan3, Akshay Gupte6, Lakshmi Murali7, a1111111111 Chhaya Valvi5, Soumya Swaminathan8¤, Amita Gupta2,6, for the CTRIUMPH Study Team¶ a1111111111 a1111111111 1 Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India, 2 Johns Hopkins University School of Medicine, Baltimore, United States of America, 3 Byramjee- Jeejeebhoy Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India, 4 Johns Hopkins University±India office, Pune, India, 5 Department of Medicine, Byramjee Jeejeebhoy Government Medical College, Pune, India, 6 Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America, 7 Department of Chest Medicine, Government Headquarters Hospital, Thiruvallur, India, 8 Indian OPEN ACCESS Council of Medical Research, New Delhi, India Citation: Chandrasekaran P, Mave V, ¤ Current address: DDP, World health Organization, Geneva, Switzerland Thiruvengadam K, Gupte N, Shivakumar SVBY, ¶ Members of the CTRIUMPh Study
  • Safety of the Two-Step Tuberculin Skin Test in Indian Health Care Workers

    Safety of the Two-Step Tuberculin Skin Test in Indian Health Care Workers

    International Journal of Mycobacteriology 3 (2014) 247– 251 HOSTED BY Available at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/IJMYCO Safety of the two-step tuberculin skin test in Indian health care workers Devasahayam J. Christopher a,*, Deepa Shankar a,1, Ashima Datey a,2, Alice Zwerling b,3, Madhukar Pai c,4 a Department of Pulmonary Medicine, Christian Medical College, Vellore 632004, Tamil Nadu, India b Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, E6133, Baltimore, MD 21205, USA c McGill University, Department of Epidemiology AND Biostatistics, 1020 Pine Ave West, Montreal, QC H3A 1A2, Canada ARTICLE INFO ABSTRACT Article history: Background: Health care workers (HCW) in low and middle income countries are at high risk Received 25 September 2014 of nosocomial tuberculosis infection. Periodic screening of health workers for both TB Accepted 2 October 2014 disease and infection can play a critical role in TB infection control. Occupational health Available online 23 October 2014 programs that implement serial tuberculin skin testing (TST) are advised to use a two-step baseline TST. This helps to ensure that boosting of waned immune response is not mis- Keywords: taken as new TB infection (i.e. conversion). However, there are no data on safety of the Tuberculosis two-step TST in the Indian context where HCWs are repeatedly exposed. Tuberculin skin test (TST) Materials and methods: Nursing students were recruited from 2007 to 2009 at the Christian Two-step tuberculin skin test Medical College and Hospital, Vellore, India. Consenting nursing students were screened Healthcare workers with a baseline two-step TST at the time of recruitment.
  • Tuberculin Skin Testing

    Tuberculin Skin Testing

    Tuberculin Skin Testing What is it? Classification of the Tuberculin Skin The Mantoux tuberculin skin test (TST) is one method Test Reaction of determining whether a person is infected with Mycobacterium tuberculosis. Reliable administration • An induration of 5 or more millimeters is considered and reading of the TST requires standardization of positive in procedures, training, supervision, and practice. » People living with HIV » A recent contact of a person with How is the TST Administered? infectious TB disease The TST is performed by injecting 0.1 ml of tuberculin » People with chest x-ray findings purified protein derivative (PPD) into the inner surface suggestive of previous TB disease of the forearm. The injection should be made with a » People with organ transplants tuberculin syringe, with the needle bevel facing upward. The TST is an intradermal injection. When placed » Other immunosuppressed people (e.g., patients correctly, the injection should produce a pale elevation of on prolonged therapy with corticosteroids the skin (a wheal) 6 to 10 mm in diameter. equivalent to/greater than 15 mg per day of prednisone or those taking TNF-α antagonists) • An induration of 10 or more millimeters is considered How is the TST Read? positive in The skin test reaction should be read between 48 and 72 » People born in countries where TB disease is hours after administration by a health care worker trained common, including Mexico, the Philippines, to read TST results. A patient who does not return within Vietnam, India, China, Haiti, and Guatemala, 72 hours will need to be rescheduled for another skin test.
  • Tuberculosis Verrucosa Cutis with Bilateral Pulmonary Tuberculosis

    Tuberculosis Verrucosa Cutis with Bilateral Pulmonary Tuberculosis

    98 Wardhani et al. Med J Univ Indon Tuberculosis Verrucosa Cutis with Bilateral Pulmonary Tuberculosis Tina Wardhani, Adhi Djuanda, Sri Adi Sularsito Abstrak Seorang laki-laki berusia 28 sejak 16 tahun lalu menderita bintil kecil, keras, kasar, dan tidak nyeri pada punggung kaki kanan. Dalam 2 tahun ini kelainan kulit menjadi tebal serta neluas dan pada paha kanan tinbul kelainan kulit serupa. Dalnn 6 bulan terakhir penderita nengeluh batuk-batuk kering, detrran, nudah lelah dan tidak nafsu makan. Pada peneriksaan fisik tatnpak penderita sakit dengan tubuh yang kurus. Terdapat petnbesaran kelenjar getah bening regional pada lipat paha kanan. Alat-alat dalam tidak nenuniukkan kelainan dan suhu nonnal. Pada peneriksaan kulit di punggung kaki kanan didapatkan jaringan hiperkeratosis berukuran 8 x 3 cm, nerah kecoklatan, dengan erosi, pus, darah, krusta, skuatna- Juga didapatijaringan hiperkeratosis berukuran 5 x 5 an dengan krusta dan skuatna sedikit proksitnal dari lesi pertana. Pada paha kanan bagian anterior terdapatjaringan hiperkeratosis berukuran 12 x 5 cm, serpiginosa, dengan erosi, pus , darah, krusta dan skuatna. Pada diaskopi tidak dijunpai apple jellyJike appearance. Petneriksaan laboratorium menunjukkan peningkatan laju endap darahyaitu 86 mny'jam dan tes fungsi hati dalatn batas nonnal. Pada petneriksaan foto toraks didapatkan ganbaran tuberkulosis paru bilateral disertai hasil positif pada petneriksaan basil tahan asam dalan sputmn. Tes tuberkulin dengan PPD 5 TU nenberi hasil positif kuat. Hasil kultur jatnur dan nikrobakteriutn negatif. Hasil petneriksaan histopatologik tidak bertentangan dengatt tnberkulosLs kutis verukosa. Pengohatan dengan obat antituberkulosis yang terdiri atas rifampisin 450 ng/hari, pirazinanid 1OO0 mg/hari, dan isoniazid jOO ng/hari nenunjukkan perbaikan klinis setelah 3 nûnggu.
  • Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level

    Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level

    Introduction for the treatment of bedaquiline of multidrug-resistant tuberculosis at country level Introduction of bedaquiline for the treatment of multidrug-resistant tuberculosis at country level Implementation plan ISBN 978 92 4 150857 5 Introduction of bedaquiline for the treatment of multidrug- resistant tuberculosis at country level This document is a complement to the WHO interim policy guidance on the use of bedaquiline in the treatment of multidrug- resistant tuberculosis that was developed in compliance with the process for evidence gathering, assessment and formulation of recommendations, as outlined in the WHO Handbook for Guideline Development (version March 2010; available at http://apps. who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf ). WHO Library Cataloguing-in-Publication Data: Introduction of bedaquiline for the treatment of multi-drug resistant tuberculosis at country level: implementation plan. 1.Antitubercular Agents – therapeutic usage. 2.Tuberculosis, Multidrug-Resistant – drug therapy. 3.Mycobacterium tuberculosis – isolation and purification. 4.Diarylquinolines – therapeutic use. I.World Health Organization. ISBN 978 92 4 150857 5 (NLM classification: WF 360) © World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission
  • The Interview with Robert Koch Held by Huseyin Hulki and the Ottoman

    The Interview with Robert Koch Held by Huseyin Hulki and the Ottoman

    Vaccine 37 (2019) 2422–2425 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine The interview with Robert Koch held by Huseyin Hulki and the Ottoman delegation on tuberculin therapy q ⇑ Gulten Dinc a, , Ayten Arikan b a Department of History of Medicine and Ethics, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, 34098 Istanbul, Turkey b Department of History of Medicine and Ethics, Istanbul Yeni Yuzyil University, Faculty of Medicine, 34001 Istanbul, Turkey article info abstract Article history: Robert Koch (1843–1910), who was one of the significant representatives of the golden age of microbi- Received 19 November 2018 ology, claimed to have discovered the tuberculin/vaccine therapy in 1890. During that era, the Received in revised form 14 March 2019 Ottoman Empire closely followed the important developments in the field of microbiology. For this rea- Accepted 19 March 2019 son, it was decided that a delegation should have been sent to Germany to observe the lecture ‘‘On Available online 25 March 2019 Bacteriological Research” to be delivered by Koch on August 3, 1890 during the 10th International Congress of Medicine to be held in Berlin. The delegation travelled to Germany and carried out observa- Keywords: tions and met Koch in the meanwhile. Among the delegation sent to Berlin there was also Dr. Huseyin Huseyin Hulki Hulki Bey, who graduated from the Military School of Medicine in 1885, and could speak French, Robert Koch Tuberculin therapy Greek, Farsi and Arabic. One of the young professors of the medical school, Dr. H. Hulki gathered his History of tuberculosis memories on the trip to Berlin in a book after his return.